Released May 13, 2024, after the close
10-Q filed May 13, 2024, 43 days after period end · 0000950170-24-058718
Q1 2024 · 10-Q
Revenue$13.01M$13.01M +2.6% vs Q1 2023−88.6% vs Q4 2023
Net Income-$58.21M-$58.21M N/M vs Q1 2023N/M vs Q4 2023
EPS Diluted-$0.59-$0.59 N/M vs Q1 2023no prior Q4 2023 on file
Operating Income-$56,591,000N/M
Operating Cash Flow-$64,741,000N/M
Margins · derived
Operating margin-435.0%−101.8 pt vs Q1 2023
Net margin-447.5%−52.6 pt vs Q1 2023
What the release said
The release
Same quarter
| Metric | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|
| Revenue | $13.01M | $12.67M | $5.90M | $14.66M |
| Net Income | -$58.21M | -$50.05M | -$39.11M | -$30.36M |
| EPS Diluted | -$0.59 | -$0.85 | -$0.84 | -$0.66 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR